VEGF-C human
SIGMA/SRP6256 - recombinant, expressed in HEK 293 cells, ≥97% (SDS-PAGE)
Synonym: Flt4-L; VRP
Product Type: Chemical
VEGF Pathway Research areas: Angiogenesis, Metastasis, Hypoxia, Osteogenesis, Developmental biology Disease areas: Cancer, Osteoporosis, Ischemic stroke, Inflammation, Rheumatoid Arthritis, Diabetes See also: SRP3182; SRP4363; V5765; SRP4634; SRP4364; SRP4365, SRP3184
Immunoblotting VEGF-C Cat. No. SRP6256, Human recombinant VEGF-C.
| assay | ≥97% (SDS-PAGE) |
| biological source | human |
| form | lyophilized powder |
| impurities | <1 EU/μg endotoxin (LAL test) |
| mol wt | calculated mol wt 15 kDa |
| observed mol wt 18-23 kDa (DTT-reduced. Protein migrates due to glycosylation. Thr 103 is the predicted N-terminus .) | |
| packaging | pkg of 10 μg |
| potency | 0.15-0.7 μg/mL |
| recombinant | expressed in HEK 293 cells |
| shipped in | wet ice |
| storage temp. | −20°C |
| tag | 6-His tagged (C-terminus) |
| UniProt accession no. | P49767   |
| General description: | Vascular endothelial growth factor C is also known as VEGFC, Flt4-L and VRP; it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parallel fashion. VEGFC is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis, lymphangiogenesis and endothelial cell growth and survival, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor D (VEGF-D). VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Overexpression of VEGF-C causes lymphatics to enlarge possibly facilitates metastasis. |
| Physical form: | Lyophilized from 0.22 μm filtered solution in PBS. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization. |
| Reconstitution: | Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 μg/mL. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥97% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |